ALAMEDA, Calif. & FREMONT, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American and TASE: BTX), and Asterias Biotherapeutics, Inc. (“Asterias”) (NYSE American ...
BioTime, Inc. and the California Institute for Regenerative Medicine Sign Distribution Agreement for GMP-Compliant Human Embryonic Stem Cell Lines ALAMEDA, Calif ...
MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--Asterias Biotherapeutics, Inc. and BioTime, Inc. (NYSE MKT: BTX) jointly announced today the closing of the transactions under the Asset ...
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement with ...
BioTime, Inc. announced an agreement with the California Institute for Regenerative Medicine (CIRM) to make five clinical-grade human Embryonic Stem (hES) cell lines available to California-based ...
BioTime, Inc.Peter GarciaChief Financial Officer510-521-3390, ext 367orJudith Segall510-521-3390, ext 301 BioTime, Inc. (NYSE MKT: BTX) today announced the appointment of Jeffrey Janus as its Vice ...
BioTime and OncoCyte Corporation Publish Data on the Gene as a Marker and Potential Diagnostic for a Wide Array of Human Cancers BioTime, Inc.Peter Garcia, 510-521-3390 ext. 367Chief Financial ...
With Ocata Therapeutics being acquired by Astellas Pharma, a very similar company based on its therapeutic stem cell platform and IP, BioTime, Inc., could be next. Japan's recent legislation has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback